Cerus Corp

  • Safety Score
  • Market Cap $233.83M
  • PE -12
  • Debt $85.10M
  • Cash $20.59M
  • EV $298.34M
  • FCF $6.71M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$18.99M
EBIT-$12.10M
ROE-34%
ROA-6%
FCF$6.71M
Equity$56.24M
Growth Stability1
PE-12.31
PB4.16
P/FCF34.87
Price/Cash0.09
Debt/Equity1.51
Debt/FCF12.69
Sales CAGR3%
Equity CAGR-2%
Earnings Growth YoY-20%
Earnings Growth QoQ201%
Sales CAGR 5Y1%
Equity CAGR 5Y-16%
Equity CAGR 3Y-11%
Market Cap$233.83M
Assets$206.78M
Total Debt$85.10M
Cash$20.59M
Shares Outstanding187.07M
EV298.34M
Safety Score72%
Working Capital91.83M
Current Ratio2.32
Shares Growth 3y2%
Equity Growth QoQ-1%
Equity Growth YoY12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

SEC Filings

Direct access to Cerus Corp (CERS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Cerus Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Cerus Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Cerus Corp Discounted Cash Flow

Fully customizable DCF calculator online for Cerus Corp.

= $67M
012345678910TV
fcf$6.7M$6.7M$6.7M$6.7M$6.7M$6.7M$6.7M$6.7M$6.7M$6.7M$6.7M$67M
DCF$6.1M$5.5M$5M$4.6M$4.2M$3.8M$3.4M$3.1M$2.8M$2.6M$26M
Value$67M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-163%-160%-118%-76%-76%-52%-34%-23%-20%-10%-
ROA--59%-58%-34%-40%-26%-21%-16%-15%-7%-6%
ROE--109%-156%-68%-125%-58%-64%-62%-70%-37%-34%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--0.36-0.57-0.93-0.53-0.93-1.57-2.53-1.679.8912.69
Debt over Equity0.210.340.770.350.690.380.641.021.51.481.51
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-15%31%48%23%22%40%18%-1%8%1%
Earnings YoY growth-13%-4%-5%24%-16%-9%-21%-12%-44%-
Equity YoY growth--39%-33%117%-32%82%-18%-20%-22%6%-16%
FCF YoY growth-4%-3%-38%131%-43%-18%-21%73%-118%-